NCT04958031 - A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

February 13, 2025

Study Completion Date

February 13, 2025

Conditions

Apathy in Dementia

Interventions

DRUG

CVL-871 1.0 mg

CVL-871 1.0 mg, oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-7)

DRUG

CVL-871 3.0 mg

CVL-871 3.0 mg QD oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-21)

DRUG

Placebo

Placebo QD, oral (tablet), once per day for 12 weeks

Trial Locations (20)

10312

Staten Island, New York, Staten Island

19001

Abington, Pennsylvania, Abington

22031

Fairfax, Virginia, Fairfax

29403

Charleston, South Carolina, Charleston

30030

Decatur, Georgia, Decatur

32819

Orlando, Florida, Orlando

33122

Miami, Florida, Miami

33180

Miami, Florida, Miami

33414

Wellington, Florida, Wellington

33445

Delray Beach, Florida, Delray Beach

43210

Columbus, Ohio, Columbus

72114

Little Rock, Arkansas, Little Rock

85258

Scottsdale, Arizona, Scottsdale

92123

San Diego, California, San Diego

92705

Santa Ana, California, Santa Ana

06510

New Haven, Connecticut, New Haven

02360

Plymouth, Massachusetts, Plymouth

T2N 4N1

Calgary, Alberta, Calgary

V8R 1J8

Victoria, British Columbia, Victoria

M4N 3M5

Toronto, Ontario, Toronto